Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.43 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7327788 | 0.98 | ST14 (0.59) | ST14CA2CA9LMNAHTT | |
| SCHEMBL30503474 | 0.88 | ST14 (0.63) | ST14CA2CA9CA12CA1 | |
| SCHEMBL28416786 | 0.86 | ST14 (0.56) | ST14CA2CA9LMNAHTT | |
| SCHEMBL4104833 | 0.82 | KMT2A (0.62) | ST14F2KMT2AALDH1A1 | |
| SCHEMBL24892365 | 0.81 | ST14 (0.55) | ST14CA2CA9LMNACA12 | |
| SCHEMBL20486525 | 0.81 | FOLH1 (0.50) | CA2CA1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL3883713 | 0.81 | KMT2A (0.61) | ST14F2KMT2AALDH1A1 | |
| SCHEMBL17198821 | 0.80 | NPC1 (0.55) | ST14CA2CA9LMNACA12 | |
| Hydrochloric Acid SCHEMBL7324472 | 0.80 | USP28 (0.49) | CA2CA1HDAC2HDAC8HDAC6 | |
| SCHEMBL12401907 | 0.80 | ST14 (0.51) | ST14CA2LMNACA1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4191779-A | P-SUBSTITUTED BENZOIC ACID | STANLEY DRUG PRODUCTS, INC. (US) | 1980-03-04 | — | — | US | claimed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-113660957-A | Compositions, methods, and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3589631-B1 | IMIDAZO[4,5-C]RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-09-08 | — | — | US | disclosed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2020-03-19 | — | — | US | disclosed |
| WO-2018160552-A1 | IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-0218027-B1 | NOVEL GUANIDINOMETHYLBENZOIC ACID DERIVATIVES | Kabushiki Kaisha Med-Creat (JP) | 1989-09-20 | — | — | EP | disclosed |
| EP-0218027-A1 | Novel guanidinomethylbenzoic acid derivatives | Kabushiki Kaisha Med-Creat (JP) | 1987-04-15 | — | — | EP | disclosed |
| US-4191779-A | P-SUBSTITUTED BENZOIC ACID | STANLEY DRUG PRODUCTS, INC. (US) | 1980-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | IL4, IFNG, IFNAR1 | ST14 2613/4885CA2 3140/4885CA9 4125/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | ST14 1010/4885CA2 4583/4885CA9 3807/4885 |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | IL4, IFNG, IFNAR1 | ST14 2613/4885CA2 3140/4885CA9 4125/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | ST14 1783/4885CA2 2367/4885CA9 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.